6 Blue Chip Stocks Trading Well Below Their Highs

The article compares six blue-chip stocks trading at least 20% below their highs: Nike (80%), Pfizer (54%), Disney (39%), Home Depot (32%), Intel (27%) and Goldman Sachs (23%). It presents mixed fundamentals: Nike sales fell 4% year over year in fiscal Q1 2027 and management forecasts another sales decline, while Goldman Sachs reported Q3 equities revenue up 72% and investment-banking fees up 21%, and Intel sales rose 25% year over year in fiscal Q2 2026. The author sees potential value in some names but flags valuation, business and macroeconomic risks, including persistent inflation and high interest rates weighing on Home Depot.

Analysis

Treat the sell-off list as a dispersion trade, not a broad blue-chip rebound. The clearest competitive mechanism is Nike’s lost shelf space and product momentum: continued share gains by Deckers (DECK) and other performance brands could pressure Nike’s pricing and wholesale reorders before headline revenue stabilizes, while DICK’S Sporting Goods (DKS) may gain from a broader brand mix. A Nike recovery under Elliott Hill is the key counter-risk; verify sell-through, inventory and wholesale orders before sizing.

Intel’s AI-CPU narrative may be real, but sales growth alone does not establish attractive economics. With profitability challenged and the stock already sharply higher, execution on gross margins, foundry losses and cash generation—not AI demand headlines—should govern the multiple. Goldman Sachs (GS) has more cyclical earnings exposure than a simple “rate fears” framing suggests: volatile markets can support trading revenue but can also defer issuance and underwriting. Strong recent fees are not proof of a durable backlog.

For Pfizer (PFE), a high indicated yield is not a floor if cash generation, patent erosion and pipeline replacement disappoint; trailing P/E is particularly uninformative after losses. Disney (DIS) needs sustained streaming economics to offset linear-TV erosion, while Home Depot (HD) remains exposed to housing turnover and financing costs. The article supplies no current cash-flow coverage, backlog, valuation or sell-through detail to establish bargain levels. Its forward-dated earnings and IPO claims also warrant source verification before trading. Near term, sentiment and rates can dominate; over 1–3 months, guidance and operating metrics matter; over 6–18 months, share recovery, patent replacement and streaming profitability determine outcomes.

Key Decisions for Investors

• Relative-value watch: consider short NKE versus long DECK only if upcoming wholesale orders and sell-through confirm Nike is still losing share; keep sizing modest and exit if Nike’s comparable sales and channel inventory improve for consecutive reports. This isolates brand execution better than buying a “down-from-high” basket.
• Do not chase INTC on AI headlines. Require evidence of improving gross margins, foundry cash use and free cash flow before adding; a deterioration in those metrics would falsify the recovery case and leave the elevated sales multiple vulnerable.
• Avoid treating PFE’s yield as a standalone buy signal. Verify dividend coverage from operating cash flow, debt trajectory and clinical/pipeline updates; reassess if coverage weakens or key replacement programs slip.
• Keep GS and HD as catalyst watches rather than dip buys: for GS, track underwriting backlog and issuance activity; for HD, track housing turnover, rate expectations and comparable sales. A sustained deterioration in either operating measure would argue against a rebound thesis.